, Volume 36, Issue 6, pp 1201–1208

Unfractionated Heparin Ameliorates Lipopolysaccharide-Induced Lung Inflammation by Downregulating Nuclear Factor-κB Signaling Pathway

  • Xu Li
  • ZhiLiang Li
  • Zhen Zheng
  • Yina Liu
  • Xiaochun Ma


The present study aimed to determine the protective effects and the underlying mechanisms of unfractionated heparin on lipopolysaccharide (LPS)-induced endotoxemia and lung injury in rats. Rats were injected intravenously with LPS at 6 mg/kg. We examined the therapeutic effects of unfractionated heparin (100 or 300 U/kg) on LPS-induced endotoxemia by dosing intravenously simultaneously after LPS challenge. The animal lung edema degree was evaluated by wet/dry weight ratio. The levels of inflammatory mediators including interleukin-1β (IL-1β) and interleukin-6 (IL-6) were assayed by enzyme-linked immunosorbent assay and quantitative real-time RT-PCR. The activation of nuclear factor-κB (NF-κB) was evaluated by Western blotting. The investigations revealed that treatment with unfractionated heparin can attenuate inflammatory responses in a rat model of LPS-induced acute lung injury, and the effect was much better in 300 U/kg group. The mechanisms by which unfractionated heparin exerts its anti-inflammatory effect are correlated with inhibition of IL-1β and IL-6 production via inactivation of NF-κB.


unfractionated heparin lipopolysaccharide endotoxemia acute lung injury nuclear factor-κB 


  1. 1.
    MacLaren, R., and K.A. Stringer. 2007. Emerging role of anticoagulants and fibrinolytics in the treatment of acute respiratory distress syndrome. Pharmacotherapy 27(6): 860–873.PubMedCrossRefGoogle Scholar
  2. 2.
    Cepkova, M., and M.A. Matthay. 2006. Pharmacotherapy of acute lung injury and the acute respiratory distress syndrome. Journal of Intensive Care Medicine 21: 119–143.PubMedCrossRefGoogle Scholar
  3. 3.
    Frutos-Vivar, F., N.D. Ferguson, and A. Esteban. 2006. Epidemiology of acute lung injury and acute respiratory distress syndrome. Seminars in Respiratory and Critical Care Medicine 27: 327–336.PubMedCrossRefGoogle Scholar
  4. 4.
    Rubenfeld, G.D., E. Caldwell, E. Peabody, et al. 2005. Incidence and outcomes of acute lung injury. The New England Journal of Medicine 353: 1685–1693.PubMedCrossRefGoogle Scholar
  5. 5.
    Ware, L.B., E. Camerer, K.E. Welty-Wolf, et al. 2006. Bench to bedside: targeting coagulation and fibrinolysis in acute lung injury. American Journal of Physiology. Lung Cellular and Molecular Physiology 291(3): L307–L311.PubMedCrossRefGoogle Scholar
  6. 6.
    Bastarache, J.A., L.B. Ware, and G.R. Bernard. 2006. The role of the coagulation cascade in the continuum of sepsis and acute lung injury and acute respiratory distress syndrome. Seminars in Respiratory and Critical Care Medicine 27: 365–376.PubMedCrossRefGoogle Scholar
  7. 7.
    Schultz, M.J., J.J. Haitsma, H. Zhang, et al. 2006. Pulmonary coagulopathy as a new target in therapeutic studies of acute lung injury or pneumonia: a review. Critical Care Medicine 34: 871–877.PubMedGoogle Scholar
  8. 8.
    Sapru, A., J.L. Wiemels, J.S. Witte, et al. 2006. Acute lung injury and the coagulation pathway: potential role of gene polymorphisms in the protein C and fibrinolytic pathways. Intensive Care Medicine 32(9): 1293–1303.PubMedCrossRefGoogle Scholar
  9. 9.
    Welty-Wolf, K.E., M.S. Carraway, T.L. Ortel, et al. 2006. Blockade of tissue factor–factor X binding attenuates sepsis-induced respiratory and renal failure. American Journal of Physiology. Lung Cellular and Molecular Physiology 290: L21–L31.PubMedCrossRefGoogle Scholar
  10. 10.
    Maybauer, M.O., D.M. Maybauer, J.F. Fraser, et al. 2006. Recombinant human activated protein C improves pulmonary function in ovine acute lung injury resulting from smoke inhalation and sepsis. Critical Care Medicine 34(9): 2432–2438.PubMedCrossRefGoogle Scholar
  11. 11.
    Yasui, H., E.C. Gabazza, S. Tamaki, et al. 2001. Intratracheal administration of activated protein C inhibits bleomycin-induced lung fibrosis in the mouse. American Journal of Respiratory and Critical Care Medicine 163: 1660–1668.PubMedCrossRefGoogle Scholar
  12. 12.
    Uchiba, M., K. Okajima, K. Murakami, et al. 1996. Recombinant thrombomodulin prevents endotoxin-induced lung injury in rats by inhibiting leukocyte activation. American Journal of Physiology 271: L470–L475.PubMedGoogle Scholar
  13. 13.
    Harada, N., K. Okajima, and M. Uchiba. 2006. Dalteparin, a low molecular weight heparin, attenuates inflammatory responses and reduces ischemia-reperfusion-induced liver injury in rats. Critical Care Medicine 34: 1883–1891.PubMedCrossRefGoogle Scholar
  14. 14.
    Yagmurdur, M.C., E. Turk, G. Moray, et al. 2005. Effect of heparin on bacterial translocation and gut epithelial apoptosis after burn injury in the rat: dose-dependent inhibition of the complement cascade. Burns 31: 603–609.PubMedCrossRefGoogle Scholar
  15. 15.
    Matzner, Y., G. Marx, R. Drexler, et al. 1984. The inhibitory effect of heparin and related glycosaminoglycans on neutrophil chemotaxis. Thrombosis and Haemostasis 52: 134–137.PubMedGoogle Scholar
  16. 16.
    Pahl, H.L. 1999. Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 18: 6853–6866.PubMedCrossRefGoogle Scholar
  17. 17.
    Zingarelli, B. 2005. Nuclear factor-kappaB. Critical Care Medicine 33: S414–S416.PubMedCrossRefGoogle Scholar
  18. 18.
    Liu, S.F., and A.B. Malik. 2006. NF-kappa B activation as a pathological mechanism of septic shock and inflammation. American Journal of Physiology. Lung Cellular and Molecular Physiology 290: L622–L645.PubMedCrossRefGoogle Scholar
  19. 19.
    Grisham, M.B., L.A. Hernandez, and D.N. Granger. 1986. Xanthine oxidase and neutrophil infiltration in intestinal ischemia. American Journal of Physiology 251: G567–G574.PubMedGoogle Scholar
  20. 20.
    Smith, K.M., J.D. Mrozek, S.C. Simonton, et al. 1997. Prolonged partial liquid ventilation using conventional and high-frequency ventilatory techniques: gas exchange and lung pathology in an animal model of respiratory distress syndrome. Critical Care Medicine 25: 1888–1897.PubMedCrossRefGoogle Scholar
  21. 21.
    Gando, S. 2010. Microvascular thrombosis and multiple organ dysfunction syndrome. Critical Care Medicine 38(2): S35–S42.PubMedCrossRefGoogle Scholar
  22. 22.
    Schwartz, M.D., E.E. Moore, F.A. Moore, et al. 1996. Nuclear factor-kappaB is activated in alveolar macrophages from patients with acute respiratory distress syndrome. Critical Care Medicine 24(8): 1285–1292.PubMedCrossRefGoogle Scholar
  23. 23.
    Bhatia, M., and S. Moochhala. 2004. Role of inflammatory mediators in the pathophysiology of acute respiratory distress syndrome. The Journal of Pathology 202: 145–156.PubMedCrossRefGoogle Scholar
  24. 24.
    Tyrell, D.J., S. Kilfeather, and C.P. Page. 1995. Therapeutic uses of heparin beyond its traditional role as an anticoagulant. Trends in Pharmacological Sciences 16: 198–204.PubMedCrossRefGoogle Scholar
  25. 25.
    Morrison, A.M., P. Wang, and I.H. Chaudry. 1996. A novel nonanticoagulant heparin prevents vascular endothelial cell dysfunction during hyperdynamic sepsis. Shock 6: 46–51.PubMedCrossRefGoogle Scholar
  26. 26.
    Li, X., Z. Zheng, X. Li, et al. 2012. Unfractionated heparin inhibits lipopolysaccharide-induced inflammatory response through blocking p38 MAPK and NF-κB activation on endothelial cell. Cytokine 60(1): 114–121.PubMedCrossRefGoogle Scholar
  27. 27.
    Cinel, I., and R.P. Dellinger. 2007. Advances in pathogenesis and management of sepsis. Current Opinion in Infectious Diseases 20: 345–352.PubMedCrossRefGoogle Scholar
  28. 28.
    Li, X., Z. Zheng, Y.R. Mao, et al. 2012. Unfractionated heparin promotes LPS-induced endothelial barrier dysfunction: a preliminary study on the roles of angiopoietin/Tie2 axis. Thrombosis Research 129(5): e223–e228.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Xu Li
    • 1
  • ZhiLiang Li
    • 1
  • Zhen Zheng
    • 1
  • Yina Liu
    • 1
  • Xiaochun Ma
    • 1
  1. 1.Department of Intensive Care Unitthe First Affiliated Hospital, China Medical UniversityShenyangPeople’s Republic of China

Personalised recommendations